Key result
Secondary prevention aspirin use tracked to identify utilization changes and factors linked to stopping therapy.
Why the study?
It was unknown whether aspirin use for secondary prevention changed from 2015 to 2020 amid negative messaging and what factors were associated with stopping therapy among adults with atherosclerotic cardiovascular disease.
Answers are grounded in this paper and cite their sources.
Decreasing aspirin use for secondary prevention amid negative messaging may reflect patient concerns; leaves open causal drivers and need for prospective adherence trials.
This cross-sectional study assesses whether aspirin use for secondary prevention changed from 2015 to 2020 and investigates the factors associated with stopping therapy among adults with atherosclerotic cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Hof et al. (2026) studied this question. Aspirin use for secondary prevention in adults with cardiovascular disease was evaluated to identify utilization changes and factors linked to stopping therapy from 2015 to 2020.
Synapse has enriched 10 related papers. Consider them for comparative context: